A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

  • Spinal Muscular Atrophy (SMA)
Trial Status:

Not yet recruiting

This trial runs in
Countries
Trial Identifier:

NCT05808764 BN44619

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT05808764 , BN44619 Trial Identifier
      Risdiplam Treatments
      Muscular Atrophy, Spinal Condition
      Official Title

      A Phase IV, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

      Eligibility Criteria

      All Gender
      ≤ 19 Days Age
      No Healthy Volunteers
      Inclusion Criteria
      • Male or female newborn infant aged <20 days at first dose
      • Newborn infants with genetic diagnosis of 5q-autosomal recessive SMA or newborn infants identified as positive for SMA via newborn screening or via prenatal testing.
      • Gestational age equal to or greater than 37 weeks
      • Receiving adequate nutrition and hydration at the time of screening
      • Adequately recovered from any acute illness at baseline and considered well enough to participate in the study
      • Parent/caregiver is willing to consider nasogastric, nasojejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator.
      Exclusion Criteria
      • Presence of clinical symptoms or signs consistent with SMA Type 0
      • In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
      • Systolic blood pressure or diastolic blood pressure or heart rate abnormalities
      • Presence of clinically relevant electrocardiogram (ECG) abnormalities
      • The infant (or the person breastfeeding the infant) taking any of the following: any inhibitor of CYP3A4 taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing, any inducer of CYP3A4 taken within 4 weeks (or within 5 times the elimination half-life, whichever is longer prior to dosing, and/or use of any multidrug and toxin extrusion (MATE) substrates taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing
      • Concurrent or previous administration of nusinersen or onasemnogene abeparvovec
      • Clinically significant abnormalities in laboratory test

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Spinal Muscular Atrophy (SMA)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now